[1] [1] HERNANDO C E, SANCHEZ S E, MANCINI E, et al. Genome wide comparative analysis of the effects of PRMT5 and PRMT4/CARM1 arginine methyltransferases on the Arabidopsis thaliana transcriptome ［J］. BMC Genomics, 2015, 16(1): 192.

[2] [2] WYSOCKA J, ALLIS C D, COONROD S, et al. Histone arginine methylation and its dynamic regulation ［J］. Frontiers in Bioscience, 2006, 11(1): 344-355.

[3] [3] SCHURTER B T, KOH S S, CHEN D, et al. Methylation of histone H3 by coactivator-associated arginine methyltransferase 1 ［J］. Biochemistry, 2001, 40(19): 5747-5756.

[4] [4] XU W, CHEN H, DU K, et al. A transcriptional switch mediated by cofactor methylation ［J］. Science, 2001, 294(5551): 2507-2511.

[5] [5] XU W, CHO H, KADAM S, et al. A methylation-mediator complex in hormone signaling ［J］. Genes & Development, 2004, 18(2): 144-156.

[6] [6] SHISHKOVA E, ZENG H, LIU F, et al. Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition ［J］. Nature Communications, 2017, 8(1): 15571.

[7] [7] KIM Y R, LEE B K, PARK R Y, et al. Differential CARM1 expression in prostate and colorectal cancers ［J］. BMC Cancer, 2010, 10(1): 197.

[8] [8] ELAKOUM R, GAUCHOTTE G, OUSSALAH A, et al. CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features ［J］. Biochimie, 2014, 97(1): 210-218.

[9] [9] MORETTIN A, BALDWIN R M, COTE J, et al. Arginine methyltransferases as novel therapeutic targets for breast cancer ［J］. Mutagenesis, 2015, 30(2): 177-189.

[10] [10] CHENG H, QIN Y, FAN H, et al. Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes ［J］. Diagnostic Pathology, 2013, 8(1): 129.

[11] [11] PENG B L, LI W J, DING J C, et al. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor alpha-dependent transcriptional activation and breast carcinogenesis ［J］. Theranostics, 2020, 10(8): 3451-3473.

[12] [12] GOSSEN M, BUJARD H, SALFELD J G. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters ［J］. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89(12): 5547-5551.

[13] [13] GOSSEN M, FREUNDLIEB S, BENDER G, et al. Transcriptional activation by tetracyclines in mammalian cells ［J］. Science, 1995, 268(5218): 1766-1769.

[14] [14] CORBEL S Y, ROSSI F M, et al. Latest developments and in vivo use of the tet system: ex vivo and in vivo delivery of tetracycline-regulated genes ［J］. Current Opinions in Biotechnology, 2002, 13(5): 448-452.

[15] [15] HARBECK N, PENAULT-LLORCA F, CORTES J, et al. Breast cancer ［J］. Nature Reviews Disease Primers, 2019, 5(1): 66.

[17] [17] BEDFORD M T, RICHARD S. Arginine methylation an emerging regulator of protein function ［J］. Molecular Cell, 2005, 18(3): 263-272.

[18] [18] WANG L, ZENG H, WANG Q. MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs ［J］. Science Advances, 2015, 1(9): e1500463.

[19] [19] FRIETZE S, LUPIEN M, SILVER P A, et al. CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1 ［J］. Cancer Research, 2008, 68(1): 301-306.

[20] [20] MESSAOUDI S E, FABBRIZIO E, RODRIGUEZ C, et al. Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene ［J］. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103(36): 13351-13356.